MIRM — Mirum Pharmaceuticals, Inc.
MIRM dilution and offerings
- Dilution risk: Low
- Active shelf: S-3ASR (Feb 2026)
- Float: 51.7M shares
🔔 Alert me if MIRM files an offering or S-3
$87.03+1.50%
Last close: · regular session
Last 60 sessions
Dilution risk: low; active automatic shelf (S-3ASR, Feb 2026). Float: 51.7M shares. Latest SEC filing: 8-K on Nov 3, 2026. MIRM closed at $87.03 (+1.50%) on Nov 3, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for MIRM in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 334
- Website: https://www.mirumpharma.com
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Latest SEC filings for MIRM
Latest MIRM news
- Mirum outlines $715M to $720M 2026 net product sales guidance while targeting cash flow positive next year Read article
- Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases Read article
- Mirum's Livmarli meets primary goal in phase 3 trial for itch with rare liver diseases Read article
- Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript Read article
- Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases Read article
- Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases Read article
- Mirum Pharmaceuticals to report Livmarli trial results Monday Read article
- Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.